The historic rise of Viagra has long been a example of pharmaceutical success, but its legacy within the broader industry now presents questions about potential yields . Generic versions are diminishing patent protection , leading to concerns that investing in companies heavily reliant to Viagra's previous standing could be a speculative decision ,